MarketPeel
Insider Trading Intelligence
MS

Michael J. Sofia

ABUS
CHIEF SCIENTIFIC OFFICER · ARBUTUS BIOPHARMA CORP · CIK 0001635324
FILING MIX · LIFETIME78%/22%
BUYS
7
SELLS
2
TOTAL VALUE
$1.84M
COMPANIES
1
ACTIVE SINCE
Feb 2020
HOLDINGS NOW
1,485,121
AVG SELL PX
$4.96
TRADE KIND
SHOWING 9 / 9
Trades · vs SPY
Loading price series…
Performance · forward returns vs SPY
2 backtested trades · 8 horizonsHow are these numbers computed? →
Forward-return performance of every backtestable P/S trade by Michael J. Sofia, measured at 8 horizons from 7 days to 2 years. Deduped per economic event so co-filings count once. Excess return = trade return minus SPY return over the same window.
HORIZONTRADESWIN RATEINSIDER RETURNSPY RETURNMEAN EXCESSMEDIAN EXCESST-STAT
7d2+50.00%+2.89%+2.80%+0.08%+0.08%
14d2+50.00%+5.28%+2.75%+2.53%+2.53%
30d2+50.00%-0.88%+4.71%-5.59%-5.59%
60d2+50.00%-16.58%+2.75%-19.33%-19.33%
90d2+50.00%-10.07%-0.87%-9.20%-9.20%
180d2+50.00%+5.56%+2.20%+3.36%+3.36%
1y2+50.00%-4.77%+7.55%-12.32%-12.32%
2y2+50.00%+14.24%+23.99%-9.75%-9.75%
How to read this: Insider Returnis the average raw return of the filer's trades over the horizon. SPY Return is what SPY did over those same windows — reference only, not a comparison. The headline alpha number is Mean Excess = Insider − SPY; green means the filer beat SPY, red means they trailed it. Win rate is the share of individual trades where the filer beat SPY. T-statvalues above 2 mean the alpha is unlikely to be chance given the sample size. "Pending" counts trades where the horizon hasn't elapsed yet; their stats are not included in the row average.
Holdings over time
ABUS · 1,485,121 shares · as of Feb 2, 2024
0373,776747,5521,121,3271,495,1032021202220232024SHARES HELD
Trading cadence · quarterly flow
BUY SELL
2020
2020
2020
2020
2021
2021
2021
2021
2022
2022
2022
2022
2023
2023
2023
2023
2024
FLOW · 7 buys / 2 sellsCOVERAGE · 17 quarters
Form 4 filings · all activity
COMPANYTYPESHARESPRICEVALUEHELD AFTERTRADE DATEFILEDDETAILS
ABUS
ARBUTUS BIOPHARMA CORP
SALE10b5-1
10b5-1 plan
9,982$2.31$23.1K1,485,121Feb 2, 2024Feb 5, 2024View →
ABUS
ARBUTUS BIOPHARMA CORP
PURCHASEGRANT
Stock grant
109,5001,495,103Feb 1, 2024Feb 5, 2024View →
ABUS
ARBUTUS BIOPHARMA CORP
PURCHASEGRANT
Stock grant
437,800437,800Feb 1, 2024Feb 5, 2024View →
ABUS
ARBUTUS BIOPHARMA CORP
PURCHASEGRANT
Stock grant
82,2001,385,603Feb 1, 2023Feb 3, 2023View →
ABUS
ARBUTUS BIOPHARMA CORP
PURCHASEGRANT
Stock grant
328,700328,700Feb 1, 2023Feb 3, 2023View →
ABUS
ARBUTUS BIOPHARMA CORP
PURCHASEGRANT
Stock grant
285,000$2.81$800.9K285,000Jan 20, 2022Jan 20, 2022View →
ABUS
ARBUTUS BIOPHARMA CORP
SALE
Chief Scientific Officer
200,000$5.09$1.02M1,303,403Dec 1, 2021Dec 3, 2021View →
ABUS
ARBUTUS BIOPHARMA CORP
PURCHASEGRANT
Stock grant
290,000290,000Feb 13, 2021Feb 17, 2021View →
ABUS
ARBUTUS BIOPHARMA CORP
PURCHASEGRANT
Stock grant
250,000250,000Feb 17, 2020Feb 19, 2020View →
Other insiders · ABUS
Loading peer insiders…
About this filer
CIK 0001635324
ROLE
Chief Scientific Officer
PRIMARY
ABUS
COMPANIES
1
ACTIVE SINCE
Feb 2020
MARKETPEEL · /INSIDER/0001635324DATA · SEC EDGAR · FORM 4 · CONSOLIDATED TAPE
FREE · DAILY · 6 AM ET

One short email. Insider buys, congressional trades, and plain-English analysis.

Feedback